Influence of different rehabilitative aerobic exercise programs on (anti-) inflammatory immune signalling, cognitive and functional capacity in persons with MS - study protocol of a randomized controlled trial.
Activities of Daily Living
Adult
Biomarkers
/ blood
Cognition
Cytokines
/ blood
Exercise Therapy
/ methods
Exercise Tolerance
Fatigue
/ etiology
High-Intensity Interval Training
Humans
Multiple Sclerosis, Chronic Progressive
/ immunology
Multiple Sclerosis, Relapsing-Remitting
/ immunology
Quality of Life
Single-Blind Method
T-Lymphocytes, Regulatory
/ metabolism
Th17 Cells
/ metabolism
Time Factors
Treatment Outcome
Tryptophan
/ blood
Cognition
Exercise
High-intensity interval exercise
Immune signalling
Inflammation
Kynurenine pathway
Multiple sclerosis
Rehabilitation
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
08 Mar 2019
08 Mar 2019
Historique:
received:
27
11
2018
accepted:
04
03
2019
entrez:
10
3
2019
pubmed:
10
3
2019
medline:
13
4
2019
Statut:
epublish
Résumé
Studies have shown positive effects of therapeutic exercise on motor- and cognitive function as well as on psychosocial outcomes in persons with multiple sclerosis (MS). A reduction of inflammatory stress through physical exercise has been suspected as one key mechanism, mediating the positive effects of exercise in the context of MS. The primary objective of this trial is to investigate the acute and chronic effects of different exercise modalities on (anti-)inflammatory immune signalling as well as on cognitive and functional capacity in persons with MS. A two armed single-blind randomized controlled design will investigate 72 persons with relapsing remitting or secondary progressive MS (EDSS 3.0-6.0), during 3 weeks of inpatient rehabilitation. Participants will be randomized into either a high-intensity interval training (HIIT) or a moderate continuous training group; the latter represents the local standard therapy (ST). Both groups will exercise 3x per week. The HIIT group will perform 5 × 1.5-min high-intensive exercise bouts at 95-100% of their maximum heart rate (HR This study will be the first to investigate both acute and chronic effects of aerobic exercise on immune function and disease associated biomarkers in persons with MS. Combining biological analyses with cognitive and functional capacity assessments may contribute to a better understanding of responses to rehabilitative training, needed to improve exercise recommendations for persons with MS. This trial was prospectively registered at ClinicalTrials.gov ( NCT03652519 ; 29 August 2018).
Sections du résumé
BACKGROUND
BACKGROUND
Studies have shown positive effects of therapeutic exercise on motor- and cognitive function as well as on psychosocial outcomes in persons with multiple sclerosis (MS). A reduction of inflammatory stress through physical exercise has been suspected as one key mechanism, mediating the positive effects of exercise in the context of MS. The primary objective of this trial is to investigate the acute and chronic effects of different exercise modalities on (anti-)inflammatory immune signalling as well as on cognitive and functional capacity in persons with MS.
METHODS
METHODS
A two armed single-blind randomized controlled design will investigate 72 persons with relapsing remitting or secondary progressive MS (EDSS 3.0-6.0), during 3 weeks of inpatient rehabilitation. Participants will be randomized into either a high-intensity interval training (HIIT) or a moderate continuous training group; the latter represents the local standard therapy (ST). Both groups will exercise 3x per week. The HIIT group will perform 5 × 1.5-min high-intensive exercise bouts at 95-100% of their maximum heart rate (HR
DISCUSSION
CONCLUSIONS
This study will be the first to investigate both acute and chronic effects of aerobic exercise on immune function and disease associated biomarkers in persons with MS. Combining biological analyses with cognitive and functional capacity assessments may contribute to a better understanding of responses to rehabilitative training, needed to improve exercise recommendations for persons with MS.
TRIAL REGISTRATION
BACKGROUND
This trial was prospectively registered at ClinicalTrials.gov ( NCT03652519 ; 29 August 2018).
Identifiants
pubmed: 30849952
doi: 10.1186/s12883-019-1267-9
pii: 10.1186/s12883-019-1267-9
pmc: PMC6407211
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
Tryptophan
8DUH1N11BX
Banques de données
ClinicalTrials.gov
['NCT03652519']
Types de publication
Clinical Trial Protocol
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
37Subventions
Organisme : Blumenau-Léonie Hartmann-Stiftung
ID : None
Références
J Clin Invest. 1999 Mar;103(6):807-15
pubmed: 10079101
Brain. 2001 Sep;124(Pt 9):1743-53
pubmed: 11522577
Control Clin Trials. 2002 Dec;23(6):662-74
pubmed: 12505244
J Neurol. 2003 Apr;250(4):461-72
pubmed: 12700913
J Appl Physiol (1985). 2004 Feb;96(2):531-9
pubmed: 14514704
Clin Chim Acta. 2006 Feb;364(1-2):82-90
pubmed: 16139256
Behav Res Methods. 2007 May;39(2):175-91
pubmed: 17695343
J Clin Epidemiol. 2007 Dec;60(12):1234-8
pubmed: 17998077
Mediators Inflamm. 2008;2008:109502
pubmed: 19148295
Qual Life Res. 2009 Sep;18(7):873-80
pubmed: 19543809
Neurobiol Dis. 2009 Oct;36(1):51-9
pubmed: 19591937
Mult Scler. 2009 Dec;15(12):1509-17
pubmed: 19995840
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Neuropsychopharmacology. 2011 Oct;36(11):2357-67
pubmed: 21796108
Mult Scler. 2012 Jun;18(6):891-8
pubmed: 22190573
Ther Adv Neurol Disord. 2012 Mar;5(2):81-95
pubmed: 22435073
Can J Occup Ther. 2012 Jun;79(3):167-74
pubmed: 22822694
Eur J Immunol. 2012 Aug;42(8):1932-7
pubmed: 22865044
Mult Scler. 2013 Apr;19(5):613-21
pubmed: 22936334
Obes Rev. 2013 Mar;14(3):232-44
pubmed: 23171381
Br J Pharmacol. 2013 Jul;169(6):1211-27
pubmed: 23647169
Exp Clin Endocrinol Diabetes. 2013 Aug;121(8):475-82
pubmed: 24026829
Cell. 2014 Sep 25;159(1):33-45
pubmed: 25259918
Front Neurol. 2014 Dec 11;5:264
pubmed: 25566171
Neurodegener Dis. 2015;15(2):63-9
pubmed: 25591815
Front Immunol. 2015 Jan 12;5:673
pubmed: 25628622
Semin Cell Dev Biol. 2015 Apr;40:134-41
pubmed: 25773161
Eur J Haematol. 2016 Feb;96(2):152-9
pubmed: 25865148
Eur J Neurol. 2015 Oct;22 Suppl 2:3-13
pubmed: 26374508
Scand J Med Sci Sports. 2015 Dec;25 Suppl 3:1-72
pubmed: 26606383
Neuropharmacology. 2017 Jan;112(Pt B):248-263
pubmed: 26617070
Neuropharmacology. 2017 Jan;112(Pt B):264-274
pubmed: 26767951
J Allergy Clin Immunol. 2016 May;137(5):1607-1610.e8
pubmed: 26774657
Mediators Inflamm. 2016;2016:6789276
pubmed: 26903712
Front Immunol. 2016 Aug 04;7:246
pubmed: 27540379
Endocrine. 2017 Aug;57(2):262-271
pubmed: 28616851
Science. 2017 Jul 28;357(6349):
pubmed: 28751584
Mult Scler. 2018 Sep;24(10):1356-1365
pubmed: 28752800
Mult Scler. 2018 Oct;24(12):1635-1644
pubmed: 28825348
Compr Physiol. 2017 Sep 12;7(4):1307-1337
pubmed: 28915326
Lancet Neurol. 2017 Oct;16(10):848-856
pubmed: 28920890
PLoS One. 2017 Oct 24;12(10):e0186774
pubmed: 29065184
Neurodegener Dis Manag. 2017 Nov;7(6s):35-40
pubmed: 29143590
Ann Clin Transl Neurol. 2018 May 31;5(7):870-875
pubmed: 30009205
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237